Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer

被引：0
|
作者：
Miano, S. T. [1 ]
Rossi, G. [1 ]
Marsili, S. [1 ]
Petrioli, R. [1 ]
Pascucci, A. [1 ]
Francini, G. [1 ]
机构：
[1] Uoc Oncol Med Scotte, Siena, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A67
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [41] Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Sharma, Priyanka
    Abramson, Vandana Gupta
    O'Dea, Anne
    Pathak, Harsh B.
    Pessetto, Ziyan Y.
    Wang, Yen Y.
    Finke, Karissa
    Hoffmann, Marc Steven
    Elia, Manana
    Lewis, Sharon
    Scott, Jecinta
    De Jong, Jilliann
    Urban, Julia
    Heldstab, Jaimie
    LaFaver, Stephanie
    Williamson, Stephen K.
    Reed, Greg
    Kimler, Bruce F.
    Khan, Qamar J.
    Godwin, Andrew K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
    Arpino, Grazia
    De Placido, Sabino
    De Angelis, Carmine
    ANTI-CANCER DRUGS, 2015, 26 (01) : 117 - 122
  • [43] Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology
    Pluschnig U.
    Neumann H.-J.
    memo - Magazine of European Medical Oncology, 2014, 7 (2) : 119 - 121
  • [44] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Livi, Lorenzo
    Bonomo, Pierluigi
    Meattini, Icro
    Simontacchi, Gabriele
    Greto, Daniela
    Desideri, Isacco
    Meacci, Fiammetta
    Scotti, Vieri
    Cecchini, Sara
    Nori, Jacopo
    Sanchez, Luis Jose
    Orzalesi, Lorenzo
    Paiar, Fabiola
    Biti, Gianpaolo
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [45] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [46] Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience
    Lorenzo Livi
    Pierluigi Bonomo
    Icro Meattini
    Gabriele Simontacchi
    Daniela Greto
    Isacco Desideri
    Fiammetta Meacci
    Vieri Scotti
    Sara Cecchini
    Jacopo Nori
    Luis Jose Sanchez
    Lorenzo Orzalesi
    Fabiola Paiar
    Gianpaolo Biti
    Medical Oncology, 2013, 30
  • [47] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [48] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [49] ANTITUMOR ACTIVITY OF NAB-PACLITAXEL AND BEVACIZUMAB AGAINST A NEW TRIPLE NEGATIVE BREAST CANCER MODEL
    Trieu, V.
    Blackwell, K. L.
    Volk, L.
    Wilber, A.
    Desai, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 43 - 43
  • [50] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
12345